奥马佐单抗
杜皮鲁玛
医学
口服免疫疗法
免疫疗法
食物过敏
不利影响
生物标志物
过敏
免疫学
口服食物挑战赛
变应原免疫治疗
重症监护医学
特应性皮炎
免疫球蛋白E
内科学
免疫系统
抗体
生物化学
化学
作者
Sayantani Sindher,Alessandro Fiocchi,Torsten Zuberbier,Stefania Arasi,Robert A. Wood,R. Sharon Chinthrajah
标识
DOI:10.1016/j.jaip.2023.11.032
摘要
The landscape of food allergy (FA) treatment is poised for a paradigm shift with the emergence of biologic therapies. The Food and Drug Administration approval of a standardized peanut powder for oral immunotherapy in 2020 marked a milestone, signaling a departure from allergen avoidance toward proactive treatment strategies. Although oral immunotherapy has been proven effective in desensitizing patients to specific allergens, there are several limitations such as lacking standardization, a long-time commitment to achieve maintenance, and adverse events. Biologics, including omalizumab, dupilumab, and antialarmins, have shown promise in treating various allergic diseases, including FA. These biologics target the underlying immunologic pathways driving allergic reactions, offering an antigen-agnostic approach. Omalizumab (anti-IgE) has been the most studied biologic in this space and can be used both as an adjunct therapy with oral immunotherapy and as monotherapy. Dupilumab targeting IL-4 and IL-13 also shows promise as an adjunct therapy. The emergence of antialarmins further broadens the spectrum of FA treatment possibilities. Biologics represent a transformative approach to FA treatment, directly addressing the underlying mechanisms. Future research should focus on patient selection criteria, personalized biomarker panels, optimal timing of intervention, and treatment durations.
科研通智能强力驱动
Strongly Powered by AbleSci AI